Melanoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Melanoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Melanoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Melanoma laboratory tests
CDC on Melanoma laboratory tests
Melanoma laboratory tests in the news
Blogs on Melanoma laboratory tests
Directions to Hospitals Treating Melanoma
Risk calculators and risk factors for Melanoma laboratory tests

Overview

There are no laboratory findings associated with the diagnosis of melanoma. Once melanoma is diagnosed, elevated concentration of serum lactate dehydrogenase (LDH) may be suggestive of metastasis.

Laboratory Findings

• There are no laboratory findings associated with the diagnosis of melanoma. Measurement of serum LDH may be considered for follow-up among patients who have been diagnosed with stage IB-IV melanoma

LDH

• Once metastatic melanoma is diagnosed, serum lactate dehydrogenase (LDH) may be helpful for follow-up.
• For patients with stage IB-IV melanoma, measurement of serum LDH may be considered every 6-12 months.